“Functional analysis of conserved structural elements in yeast syntaxin Vam3p”. J. Biol. Chem.276 (30): 28598–605. (2001). doi:10.1074/jbc.M101644200. PMID11349128.
“A protein assembly-disassembly pathway in vitro that may correspond to sequential steps of synaptic vesicle docking, activation, and fusion”. Cell75 (3): 409–18. (1993). doi:10.1016/0092-8674(93)90376-2. PMID8221884.
Greaves, Jennifer (5 April 2009). “Regulation of SNAP-25 Trafficking and Function by Palmitoylation”. Biochemical Society Transactions38 (part 1): 163–166. doi:10.1042/BST0380163. PMID20074052.
Greaves, Jennifer (5 April 2009). “Regulation of SNAP-25 Trafficking and Function by Palmitoylation”. Biochemical Society Transactions38 (part 1): 163–166. doi:10.1042/bst0380163. PMID20074052.
Hess, EJ (1992). “Spontaneous locomotor hyperactivity in a mouse mutant with a deletion including the Snap gene on chromosome 2”. Journal of Neuroscience12 (7): 2865–2874. doi:10.1523/JNEUROSCI.12-07-02865.1992. PMID1613559.
Thompson, PM (1998). “Altered levels of the synaptosomal associated protein SNAP-25 in schizophrenia”. Biological Psychiatry43 (4): 239–243. doi:10.1016/s0006-3223(97)00204-7. PMID9513732.
Gabriel, SM (1997). “Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia”. Archives of General Psychiatry54 (6): 559–566. doi:10.1001/archpsyc.1997.01830180077010. PMID9193197.
“Catalytic Features of the Botulinum Neurotoxin A light chain Revealed by High Resolution Structure of an Inhibitory Peptide Complex”. Biochemistry47 (21): 5736–5745. (May 2008). doi:10.1021/bi8001067. PMID18457419.
“Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension”. Headache38 (6): 468–71. (1998). doi:10.1046/j.1526-4610.1998.3806468.x. PMID9664753.
“Cosmetic denervation of the muscles of facial expression with botulinum toxin. A dose-response study”. Dermatol Surg22 (1): 39–43. (1996). doi:10.1111/j.1524-4725.1996.tb00569.x. PMID8556256.
“Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin.”. Nature359 (6398): 832–5. (29 October 1992). doi:10.1038/359832a0. PMID1331807.
“The thioredoxin reductase-thioredoxin system is involved in the entry of tetanus and botulinum neurotoxins in the cytosol of nerve terminals”. FEBS Lett.587 (2): 150–5. (2013). doi:10.1016/j.febslet.2012.11.007. PMID23178719.
“The Hairpin-type Tail-Anchored SNARE Syntaxin 17 Targets to Autophagosomes for Fusion with Endosomes/Lysosomes”. Cell151 (6): 1256–1269. (December 2012). doi:10.1016/j.cell.2012.11.001. PMID23217709.
“Functional analysis of conserved structural elements in yeast syntaxin Vam3p”. J. Biol. Chem.276 (30): 28598–605. (2001). doi:10.1074/jbc.M101644200. PMID11349128.
“A protein assembly-disassembly pathway in vitro that may correspond to sequential steps of synaptic vesicle docking, activation, and fusion”. Cell75 (3): 409–18. (1993). doi:10.1016/0092-8674(93)90376-2. PMID8221884.
Greaves, Jennifer (5 April 2009). “Regulation of SNAP-25 Trafficking and Function by Palmitoylation”. Biochemical Society Transactions38 (part 1): 163–166. doi:10.1042/BST0380163. PMID20074052.
Greaves, Jennifer (5 April 2009). “Regulation of SNAP-25 Trafficking and Function by Palmitoylation”. Biochemical Society Transactions38 (part 1): 163–166. doi:10.1042/bst0380163. PMID20074052.
Hess, EJ (1992). “Spontaneous locomotor hyperactivity in a mouse mutant with a deletion including the Snap gene on chromosome 2”. Journal of Neuroscience12 (7): 2865–2874. doi:10.1523/JNEUROSCI.12-07-02865.1992. PMID1613559.
Thompson, PM (1998). “Altered levels of the synaptosomal associated protein SNAP-25 in schizophrenia”. Biological Psychiatry43 (4): 239–243. doi:10.1016/s0006-3223(97)00204-7. PMID9513732.
Gabriel, SM (1997). “Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia”. Archives of General Psychiatry54 (6): 559–566. doi:10.1001/archpsyc.1997.01830180077010. PMID9193197.
“Catalytic Features of the Botulinum Neurotoxin A light chain Revealed by High Resolution Structure of an Inhibitory Peptide Complex”. Biochemistry47 (21): 5736–5745. (May 2008). doi:10.1021/bi8001067. PMID18457419.
“Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension”. Headache38 (6): 468–71. (1998). doi:10.1046/j.1526-4610.1998.3806468.x. PMID9664753.
“Cosmetic denervation of the muscles of facial expression with botulinum toxin. A dose-response study”. Dermatol Surg22 (1): 39–43. (1996). doi:10.1111/j.1524-4725.1996.tb00569.x. PMID8556256.
“Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin.”. Nature359 (6398): 832–5. (29 October 1992). doi:10.1038/359832a0. PMID1331807.
“The thioredoxin reductase-thioredoxin system is involved in the entry of tetanus and botulinum neurotoxins in the cytosol of nerve terminals”. FEBS Lett.587 (2): 150–5. (2013). doi:10.1016/j.febslet.2012.11.007. PMID23178719.
“The Hairpin-type Tail-Anchored SNARE Syntaxin 17 Targets to Autophagosomes for Fusion with Endosomes/Lysosomes”. Cell151 (6): 1256–1269. (December 2012). doi:10.1016/j.cell.2012.11.001. PMID23217709.